ReviewThe Lancet. Global health2021
Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action.
Review in The Lancet. Global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and safety of different drugs for the treatment of leishmaniasis: a systematic review and network meta-analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- Visceral Leishmaniasis in Sub-Himalayan India (1967-2023): A Systematic Review.The American journal of tropical medicine and hygiene · 2024Pooled it
- Prevalence of human visceral leishmaniasis and its risk factors in Eastern Africa: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Widespread transmission in diverse ecotypes challenges visceral leishmaniasis control in East Africa.One health (Amsterdam, Netherlands) · 2026Article
- Lymphocyte-mediated immune responses to Leishmania infection.Nature reviews. Immunology · 2026Review
- Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases.Infectious diseases of poverty · 2026Article
- Immunoinformatics-Driven Identification of Conserved Multi-Epitope Vaccine Candidates from PDI Protein of Leishmania Donovani for Visceral Leishmaniasis.Cell biochemistry and biophysics · 2026Article
- Efficacy and cost-effectiveness of outdoor residual spraying with α-cypermethrin, pirimiphos-methyl, and deltamethrin against sand flies: a pragmatic cluster randomised controlled field trial in Uganda.Tropical medicine and health · 2026Article
- Resurgence of visceral and cutaneous leishmaniasis in Kajiado County, Kenya: A coordinated response and entomological survey.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Article
- Characteristics, treatment outcomes and factors associated with death among patients with Visceral Leishmaniasis, Uganda, 2019-2024.PLoS neglected tropical diseases · 2026Observational
- Determinants of Leishmania infection in refugee camps in Gambella and Benishangul Gumuz regional states of Ethiopia: a matched case-control study.BMC infectious diseases · 2026Article
- Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis.The Journal of antimicrobial chemotherapy · 2026Article
- Targeting environmental determinants and settlements in public health planning for the containment of visceral leishmaniasis: a One Health perspective.Frontiers in public health · 2026Article
- Leishmaniasis.Nature reviews. Disease primers · 2025Review
- Article
- Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Kala-azar elimination in India: reflections on success and sustainability.International health · 2025Article
- Prevalence of Leishmania infection in refugee camps: A serological and molecular study in Gambella and Benishangul-Gumuz, Ethiopia.PLoS neglected tropical diseases · 2025Article
- Progress and Prospects of Triazoles in Advanced Therapies for Parasitic Diseases.Tropical medicine and infectious disease · 2025Review
- Global, regional, and national burden of Visceral leishmaniasis, 1990-2021: findings from the global burden of disease study 2021.Parasites & vectors · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
East Africa is the world region most affected by visceral leishmaniasis, accounting for 45% of cases globally that were reported to WHO in 2018, with an annual incidence that is only slightly decreasing. Unlike southeast Asia, east Africa does not have a regional approach to achieving elimination of visceral leishmaniasis as a public health problem. The goal of the WHO 2021-30 Neglected Tropical Diseases road map is to reduce mortality caused by the disease to less than 1%. To achieve this goal in east Africa, it will be necessary to roll out diagnosis and treatment at the primary health-care level and implement evidence-based personal protection methods and measures to reduce human-vector contact. Investment and collaboration to develop the necessary tools are scarce. In this Health Policy paper, we propose a strategic framework for a coordinated regional approach in east Africa for the elimination of visceral leishmaniasis as a public health problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.